Adverum Biotechnologies, Inc.
ADVM
$3.81
-$0.13-3.30%
| Weiss Ratings | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.67 | |||
| Price History | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -24.40% | |||
| 30-Day Total Return | -3.30% | |||
| 60-Day Total Return | -20.46% | |||
| 90-Day Total Return | -33.74% | |||
| Year to Date Total Return | -20.63% | |||
| 1-Year Total Return | -71.07% | |||
| 2-Year Total Return | -45.57% | |||
| 3-Year Total Return | -71.57% | |||
| 5-Year Total Return | -96.18% | |||
| 52-Week High % Change | -72.17% | |||
| 52-Week Low % Change | 11.93% | |||
| Price | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.16 | |||
| 52-Week Low Price | $3.52 | |||
| 52-Week Low Price (Date) | Feb 26, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 81.96M | |||
| Enterprise Value | 1.98M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.03 | |||
| Earnings Per Share Growth | -51.95% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 82.25 | |||
| Price/Book (Q) | 0.57 | |||
| Enterprise Value/Revenue (TTM) | 1.98 | |||
| Price | $3.81 | |||
| Enterprise Value/EBITDA (TTM) | -0.02 | |||
| Enterprise Value/EBIT | -0.02 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 20.88M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 656 9323 | |||
| Address | 100 Cardinal Way Redwood City, CA 94063 | |||
| Website | adverum.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -10,287.60% | |||
| Profit Margin | -9,411.10% | |||
| Management Effectiveness | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -29.83% | |||
| Return on Equity | -- | |||
| Income Statement | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.00M | |||
| Total Revenue (TTM) | 1.00M | |||
| Revenue Per Share | $0.05 | |||
| Gross Profit (TTM) | -67.22M | |||
| EBITDA (TTM) | -99.02M | |||
| EBIT (TTM) | -102.88M | |||
| Net Income (TTM) | -94.11M | |||
| Net Income Avl. to Common (TTM) | -94.11M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 17.49% | |||
| EPS Diluted (TTM) | -6.03 | |||
| EPS Diluted Growth (Q YOY) | 60.08% | |||
| Balance Sheet | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 153.24M | |||
| Cash Per Share (Q) | $7.34 | |||
| Total Current Assets (Q) | 161.08M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 144.12M | |||
| Current Ratio (Q) | 5.824 | |||
| Book Value Per Share (Q) | $6.93 | |||
| Total Assets (Q) | 234.38M | |||
| Total Current Liabilities (Q) | 27.66M | |||
| Total Debt (Q) | 73.26M | |||
| Total Liabilities (Q) | 90.26M | |||
| Total Common Equity (Q) | 144.12M | |||
| Cash Flow | ADVM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -47.58M | |||
| Cash from Financing (TTM) | 119.93M | |||
| Net Change in Cash (TTM) | -13.19M | |||
| Levered Free Cash Flow (TTM) | -47.60M | |||
| Cash from Operations (TTM) | -85.54M | |||
